← Thiazolidinediones × blood pressure

TrialCardiovascular diabetology2008

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).

Michel Komajda et al.PubMed ↗Full text ↗Publisher ↗

  • Rosiglitazonelooks bad hereHigher 24-hour ambulatory systolic BP, higher ambulatory diastolic BP, higher 24-hour ambulatory diastolic BP.Randomised, small.

What the trial testedrandomised · 759 people · 2008

Randomised vs metformin

Probably raised 24-hour ambulatory systolic BP

+2.70+0.50 to +4.90

rosiglitazone vs metformin

As reported

difference 2.7, 95% CI 0.50–4.90

Randomised vs metformin

Probably raised 24-hour ambulatory systolic BP

+2.50+0.20 to +4.80

rosiglitazone vs metformin

As reported

difference 2.5, 95% CI 0.20–4.80

Randomised vs metformin

Probably raised ambulatory diastolic BP

+2.70+1.40 to +4.00

rosiglitazone vs metformin

As reported

difference 2.7, 95% CI 1.40–4.00

Randomised vs metformin

Probably raised ambulatory diastolic BP

+3.10+1.80 to +4.50

rosiglitazone vs metformin

As reported

difference 3.1, 95% CI 1.80–4.50

+4 more in the walkthrough ↓

Who was studied, and how

4,447people in the A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia trial, from 2001
759of them with hypertension, in this paper

The trial randomly assignedassigned by chance

rosiglitazone
metformin

Probably raised 24-hour ambulatory systolic BP+2.70

Probably raised ambulatory diastolic BP+2.70

randomised

The trial randomly assignedassigned by chance

rosiglitazone
sulfonylureas

Probably raised 24-hour ambulatory systolic BP+2.70

Probably raised 24-hour ambulatory diastolic BP+2.10

randomised

the abstract, start to end

… versus metformin (difference at 6 months 2.7 [95% CI 0.5-4.9] mmHg, p = 0.015; 12 months 2.5 [95% CI 0.2-4.8] mmHg, p = …

… BP (dBP) were comparable (6 months 2.7 [95% CI 1.4-4.0] mmHg, p < 0.001; 12 months 3.1 [95% CI 1.8-4.5] mmHg, p < …

… versus sulfonylureas at 12 months (sBP 2.7 [95% CI 0.5-4.9] mmHg, p = 0.016; dBP 2.1 [95% CI 0.7-3.4] mmHg, p = 0.003), but differences were smaller and/or not statistically significant at 6 months (sBP 1.5 [95% CI -0.6 to 3.6] mmHg, p = NS; dBP 1.3 [95% CI 0.0-2.5] mmHg, p = …

← favours treatmentfavours comparator →
could be chance
24-hour ambulatory systolic BP (sBP)rosiglitazone vs metformin
2.70.50–4.90
24-hour ambulatory systolic BP (sBP)rosiglitazone vs metformin
2.50.20–4.80
Ambulatory diastolic BP (dBP)rosiglitazone vs metformin
2.71.40–4.00
Ambulatory diastolic BP (dBP)rosiglitazone vs metformin
3.11.80–4.50
24-hour ambulatory systolic BP (sBP)rosiglitazone vs sulfonylureas
2.70.50–4.90
24-hour ambulatory diastolic BP (dBP)rosiglitazone vs sulfonylureas
2.10.70–3.40
24-hour ambulatory systolic BP (sBP)rosiglitazone vs sulfonylureas
1.5−0.60 to 3.60
24-hour ambulatory diastolic BP (dBP)rosiglitazone vs sulfonylureas
1.30.00–2.50
ThiazolidinedionesBlood pressure

Thiazolidinediones × blood pressurehelps?mixed

unlikelylikely
0.000.25 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

21 papers cite it

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
this paperpooled ittrialcites it

The trial

NCT00379769phase 34,447 enrolled2001
Full record →Abstract, authors, funding and every citing paper · PMID 18435852